Anti-VEGF (bevacizumab) or anti-VEGFR2 antibodies (DC101) significantly enhanced the trafficking of EATs into tumors and CD8(+) T cell infiltration, improving the in vivo anti-tumor effect. Here, CD8A is linked to neoplasm.